Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Ask Vendit Off-Topic Questions -- Ignore unavailable to you. Want to Upgrade?

To: Vendit™ who wrote (6514)	3/15/2005 7:13:37 AM
From: Walkingshadow	Read Replies (1) \| Respond to of 8752

True enough. But this one has a chance to move further, because the market may decide to price in the likelihood that Avastin will also be found to be effective in breast cancer (currently in clinical trials) and possibly even other cancers. It seems the general strategy might be applicable to a number of very lethal cancers, and if so, will get fast-tracked and could make a considerable impact in DNA revenues down the road because the potential market is expanding considerably. So... that's why I want to try to hang on if the market moves this further. Edit: there are at least 3 upgrades/upwards revisions of price targets for DNA so far today. T